A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas

Medical Physics

Volumn 41, Issue 8, 2014, Pages

  Thompson, Reid F ^a   Mayekar, Sonal U ^b   Zhai, Huifang ^a   Both, Stefan ^a   Apisarnthanarax, Smith ^c   Metz, James M ^a   Plastaras, John P ^a   Ben Josef, Edgar ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

IMRT; pancreas; PBS; protons; unresectable

Indexed keywords

DISEASES; DRUG PRODUCTS; LEAD; PROTON BEAMS; PROTONS; RADIOTHERAPY;

EQUIVALENT CONSTRAINTS; EQUIVALENT UNIFORM DOSE; GASTROINTESTINAL TOXICITIES; IMRT; INSTITUTIONAL CONSTRAINTS; PANCREAS; PANCREATIC CANCERS; UNRESECTABLE;

PROTON BEAM THERAPY;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CLINICAL ARTICLE; DOSIMETRY; DOUBLE SCATTERING SCANNING; DUODENUM; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; KIDNEY; LIVER; MALE; ORGANS AT RISK; PANCREAS CANCER; PENCIL BEAM SCANNING; PHOTON THERAPY; PRESCRIPTION; PROTON THERAPY; RADIATION DOSE DISTRIBUTION; SMALL INTESTINE; STOMACH; TREATMENT PLANNING; TUMOR VOLUME; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PATHOLOGY; PHOTON; RADIATION DOSE; RADIATION RESPONSE; SPINAL CORD; THERAPEUTIC USE;

PROTON;

AGED; DUODENUM; FEMALE; HUMANS; INTESTINE, SMALL; KIDNEY; LIVER; MALE; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PHOTONS; PROTON THERAPY; PROTONS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; SPINAL CORD; STOMACH; TUMOR BURDEN;

EID: 84904651715     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.4887797     Document Type: Article

References (22)

1. C. A. Iacobuzio-Donahue et al., " DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer," J. Clin. Oncol. 27 (11), 1806-1813 (2009). 10.1200/JCO.2008.17. 7188
2. P. J. Loehrer Sr. et al., " Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial," J. Clin. Oncol. 29 (31), 4105-4112 (2011). 10.1200/JCO.2011.34.8904
3. H. M. Ceha et al., " Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma," Cancer 89 (11), 2222-2229 (2000). 10.1002/1097-0142(20001201)89:11<2222::AID- CNCR10>3.0.CO;2-V
4. E. Ben-Josef et al., " A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer," Int. J. Radiat. Oncol., Biol., Phys. 84 (5), 1166-1171 (2012). 10.1016/j.ijrobp.2012.02.051
5. J. D. Murphy et al., " Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer," Int. J. Radiat. Oncol., Biol., Phys. 68 (3), 801-808 (2007). 10.1016/j.ijrobp.2006.12.053 (Pubitemid 46818734)
6. D. S. Chang et al., " Beam angle selection for intensity-modulated radiotherapy (IMRT) treatment of unresectable pancreatic cancer: Are noncoplanar beam angles necessary?," Clin. Translat. Oncol. 15 (9), 720-724 (2013). 10.1007/s12094-012-0998-5
7. E. Ben-Josef et al., " Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer," Int. J. Radiat. Oncol., Biol., Phys. 59 (2), 454-459 (2004). 10.1016/j.ijrobp.2003.11.019 (Pubitemid 38622600)
8. M. F. Moyers and D. W. Miller, " Range, range modulation, and field radius requirements for proton therapy of prostate cancer," Technol. Cancer Res. Treat. 2 (5), 445-447 (2003). (Pubitemid 37363001)
9. P. C. Park et al., " A beam-specific planning target volume (PTV) design for proton therapy to account for setup and range uncertainties," Int. J. Radiat. Oncol., Biol., Phys. 82 (2), e329-e336 (2012). 10.1016/j.ijrobp.2011.05.011
10. International Commission on Radiation Units and Measurements, " Prescribing, recording, and reporting proton-beam therapy," ICRU Report 78 (ICRU, Oxford, 2007).
11. R. F. Thompson, " RadOnc: An R package for analysis of dose-volume histogram and three-dimensional structural data," J. Rad. Oncol. Informatics 6 (1), 71-83 (2014). 10.5166/jroi-6-1-25
12. A. C. Spalding et al., " Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions," Med. Phys. 34 (2), 521-529 (2007). 10.1118/1.2426403 (Pubitemid 46185131)
13. K. R. Kozak et al., " Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment," Int. J. Radiat. Oncol., Biol., Phys. 68 (5), 1557-1566 (2007). 10.1016/j.ijrobp.2007.02. 056 (Pubitemid 47176818)
14. M. Bouchard et al., " Dose escalation with proton or photon radiation treatment for pancreatic cancer," Radiother. Oncol. 92 (2), 238-243 (2009). 10.1016/j.radonc.2009.04.015
15. A. Nakamura et al., " Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy," Int. J. Radiat. Oncol., Biol., Phys. 84 (2), 369-375 (2012). 10.1016/j.ijrobp.2011.12.026
16. P. Kelly et al., " Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer," Int. J. Radiat. Oncol., Biol., Phys. 85 (3), e143-e149 (2013). 10.1016/j.ijrobp.2012.09.035
17. L. A. Dawson et al., " The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy," Int. J. Radiat. Oncol., Biol., Phys. 51 (5), 1410-1421 (2001). 10.1016/S0360-3016(01)02653-0 (Pubitemid 33116336)
18. S. J. Dowdell et al., " Monte Carlo study of the potential reduction in out-of-field dose using a patient-specific aperture in pencil beam scanning proton therapy," Phys. Med. Biol. 57 (10), 2829-2842 (2012). 10.1088/0031-9155/57/10/2829
19. J. Huang et al., " Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma," Int. J. Radiat. Oncol., Biol., Phys. 83 (4), 1120-1125 (2012). 10.1016/j.ijrobp.2011.09. 022
20. P. Prior et al., " Consolidating duodenal and small bowel toxicity data via isoeffective dose calculations based on compiled clinical data," Pract. Radiat. Oncol. 4 (2), e125-e131 (2014). 10.1016/j.prro.2013.05.003
21. S. Yovino et al., " Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers," Int. J. Radiat. Oncol., Biol., Phys. 79 (1), 158-162 (2011). 10.1016/j.ijrobp.2009.10.043
22. R. C. Nichols Jr. et al., " Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity," Acta Oncol. 52 (3), 498-505 (2013). 10.3109/0284186X.2012.762997